Navigation Links
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Date:3/31/2008

Data expands body of evidence in high risk population using IVUS, a unique

marker for coronary atherosclerosis

CHICAGO, March 31 /PRNewswire/ -- New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS(R) (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

"We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS," said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. "While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes."

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statisticall
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
2. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
3. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
4. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
5. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... represented by ICAP Ocean Tomo , this technology discloses an ... portfolio will be auctioned off at ICAP Ocean Tomo,s Spring ... York City. (Logo: https://photos.prnewswire.com/prnh/20100614/CG20517LOGO ) ... discloses the following: An advanced hip implant ...
... 15, 2011 Survey Sampling International (SSI)—the ... sampling solutions—has appointed Chris DeAngelis to head ... support the unique sampling requirements of health-related ... of sampling science to health-focused industries, SSI ...
Cached Medicine Technology:Healthier Healing for Hip Resurfacing - ICAP Ocean Tomo Announces Auction of an Advanced Hip Cap for Electromagnetic Tissue Stimulation by Neue Magnetodyn. 2Survey Sampling International Names Chris DeAngelis to Head New SSI Health 2Survey Sampling International Names Chris DeAngelis to Head New SSI Health 3
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – ... trek of the Appalachian Trail by stepping off Springer Mountain and heading north. ... On July 26th Phil reached Connecticut and was greeted by friends and family. He ...
(Date:7/31/2015)... , ... August 01, 2015 , ... Super Bowl 50 will emanate from ... League’s biggest day each year is the Super Bowl. In the two weeks that separate ... from the host venue. The 2016 Super Bowl game will mark the 50th time it ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... of a new malaria vaccine on both humans and ... disease that causes at least one million deaths annually, ... the Pasteur Institute here injected an MSP-3-based vaccine into ... it after one month and again after four months, ...
... from National Cancer Institute, US is to start testing their ... drug metabolize, enzyme kinetics and drug action mechanisms in dogs ... ,Dr. Chand Khanna, Veterinary Oncologist said, “It turns out that ... represented in dogs and the dogs will help us prioritize ...
... very good ones nutritionally due to their numerous benefits and ... of stroke, according to an article published in the Oct. ... of seven prospective studies, five from the US, one from ... of 232,049 subjects - 90,513 men and 141,536 women - ...
... new research conducted in Helsinki, Finland, gluten-free diet ... adolescents with coeliac disease.,Coeliac disease in adolescents has ... and disruptive behavioural disorders, particularly in the phase ... 9 adolescents with coeliac disease, aged 12 to ...
... There has been an increasing focus to change work ... and relaxation to avoid mental illness and its devastating ... acceptable one in view of the results published by ... the impact of anxiety and depressive disorders on workplace ...
... claimed to be of the first of its kind, ... in a young child with attention-deficit/hyperactivity disorder//. ... of the journal Pediatrics, present the case report of ... hyperactivity, attention deficit, impulsivity, and sleep problems. ...
Cached Medicine News:Health News:Breakthrough In New Vaccine For Malaria 2Health News:Servings of fruits can help reduce the risk of stroke 2Health News:Gluten-Free Diet May Alleviate Psychiatric Symptoms In Adolescents 2Health News:Now Employers Focus On Employees Mental health 2Health News:Iron Supplementation Aid In Relief From Attention-Deficit/Hyperactivity Disorder 2
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
Medicine Products: